{"id":"pf-06947386","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated cAMP levels in immune and inflammatory cells. This suppresses the production of pro-inflammatory cytokines and chemokines, thereby reducing inflammation. The mechanism is particularly relevant for conditions driven by excessive innate immune activation.","oneSentence":"PF-06947386 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory signaling by increasing intracellular cAMP levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:13.853Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"}]},"trialDetails":[{"nctId":"NCT04927312","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-01","conditions":"Complicated Intra-abdominal Infection","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PF-06947386","genericName":"PF-06947386","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PF-06947386 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory signaling by increasing intracellular cAMP levels. Used for Systemic lupus erythematosus (SLE).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}